index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

83

 

NOTICES

152

 

 

MOTS CLES

Méta-Analyse Prostate cancer Alitretinoin Epidemiology Meta-Analysis Biologics BTK protein Beta-lactam antibiotics COVID-19 Autoimmunity Apre-milast Graft-versus-host disease Endocrine toxicity Acute Myeloid Leukaemia AML Antimicrobials ArtThese Ankylosing Sacroiliitis Placebo Atrial fibrillation Spondyloarthritis Cattle Pharmacovigilance Cardiomyopathy Autoimmune diseases Dermatology Auto-Diagnostic Azathioprine Cardiovascular risk Biologic therapy Vigibase® Pharmacoepidemiology CTLA-4 Stability Immune checkpoint inhibitors Cardiotoxicity Adverse side effects Axial spondyloarthritis Immunotherapy Biological therapy Ethics ASDAS Atopic dermatitis Anti-HCV Direct Acting Antivirals DAA Biologic drug Apremilast Drug survival Drug reaction Primary adrenal insufficiency Psoriasis Intensive care Angiotensin-converting enzyme inhibitors Cardiovascular therapy CSK tyrosine-protein kinase Antimicrobiens Antibiotic misuse Adalimumab Burden Management Bacterial rhinosinusitis Anti-TNF Sipuleucel-T Calcium channel blockers Anxiété Auto-immune hepatitis Antibiotics Etanercept Treatment Arthritis Alcohol Cancer Aging Case-Control Studies Biomédicaments Cardio-oncology Abus d'antibiotiques Infliximab Biological Therapy Quality of life Biosimilar Pharmaceuticals Psoriatic arthritis Accelerometer Addiction Glucocorticoids Amyloidosis Adolescent Immune-related adverse events Antimicrobial resistance Biomarkers Ankylosing spondylitis Ustekinumab Angiotensin receptor blockers Care pathway Anticancer drugs Access to care Arrhythmia Antibiotic resistance Anxiety Biologic Albinism

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS